Products
Online Inquiry
NSC228155
Cat. No.:
OB0225WX-2748
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
NSC228155 functions as an EGFR activator by binding to the sEGFR dimerization domain II and specifically modulating receptor tyrosine phosphorylation.
Synonym:
113104-25-9; NSC-228155; NSC 228155; 7-nitro-4-(1-oxidopyridin-1-ium-2-yl)sulfanyl-2,1,3-benzoxadiazole; 2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)pyridine 1-oxide; 2-[(7-Nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio]pyridine 1-oxide; 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]pyridin-1-ium-1-olate; 2-(7-Nitrobenzo[c][1,2,5]oxadiazol-4-ylthio)pyridine 1-oxide; 4-nitro-7-[(1-oxidopyridin-2-yl)sulfanyl]-2,1,3-benzoxadiazole; 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]-1-oxidopyridin-1-ium
CAS No.:
113104-25-9
Compound CID:
313619
Formula:
C11H6N4O4S
Formula Weight:
290.25
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
NSC228155 is used in oncology research as an inhibitor of the EGFR signaling pathway to investigate the suppression of ligand-induced receptor phosphorylation and its impact on tumor cell proliferation.
Library Information
Target:
EGFR
Receptor:
EGFR
Pathways:
Angiogenesis
Plate Number:
L6700-10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
15 mg/mL; 51.68 mM
ALogP:
1.957
HBA_Count:
3
HBD_Count:
0
Rotatable Bond:
3
